Oxford’s COVID-19 vaccine prompts immune response among old as well as young adults

Oxford’s COVID-19 vaccine prompts immune response among old as well as young adults

University of Oxford’s leading COVID-19 experimental vaccine produced similar immunogenicity responses in both old and young adults with lower adverse responses among the elderly, said the AstraZeneca Plc .

The news that older people get an immune response from the vaccine is positive as the immune system weakens with age and older people are those most at risk of dying from the virus. The results further build the body of evidence for the safety and immunogenicity of AZD1222 vaccine.

AstraZeneca did not provide detail of the data behind the statement or say when it would publish the eagerly awaited late-stage phase III trial data, which would show whether the vaccine works well enough in large scale trials for it to be approved.

The development of Oxford’s vaccine candidate known as ChAdOx1 nCoV-19 or AZD1222 began in January. The viral vector vaccine is made from a weakened form of a common cold virus that causes infections in chimpanzees.

Immunogenicity blood tests carried out on a subset of older participants echo data released in July showed that the vaccine generated “robust immune responses” in a group of healthy adults aged between 18 and 55.

AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world as it gets closer to reporting early results of a late-stage clinical trial.

Staff at a London hospital trust have been told to be ready to receive the first batches of the Oxford/AstraZeneca vaccine, The Sun newspaper reported on Monday.